Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader.
From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn.
Nader said: “I am honoured to join the board of Prevail Therapeutics.
“The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help accelerate important therapeutic advances for patients with these devastating illnesses.”
Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America leadership team of Aventis and its predecessor companies, holding a number of executive positions including senior vice president of integrated healthcare markets.
Commenting on the appointments, Asa Abeliovich, founder and chief executive officer at Prevail, said: “Francois’ leadership and proven track record in building and operating biotech companies will be invaluable as we advance our pipeline of gene therapy programmes toward the clinic.”